Skip to main content

Market Overview

Why Did Orphazyme (ORPH) Shares Skyrocket As Much As 1387% Today?

Why Did Orphazyme ORPH Shares Skyrocket As Much As 1387% Today?

Orphazyme A/S (NASDAQ: ORPH) shares skyrocketed over 300% in the regular session on Thursday.

What Happened: Shares of the Denmark-based biopharmaceutical firm touched an intraday high of $77.77, running up 1,387%. 

There was no announcement made by the company on Thursday that could explain the volatility in shares which halted trading 20 times until the afternoon.

On Thursday, volumes touched 7.56 million shares whereas the average volume is 61,335.

Orphazyme shares ended Thursday’s regular session 302.4% higher at $21 and fell 9.29% in the after-hours trading to $19.05.

Why It Matters: On May 7, in the latest press statement put out by Orphazyme, it said its application for arimoclomol, which will be branded as MIPLYFFA for Niemann-Pick disease type C, is under priority review with the U.S. Food and Drug Administration — with the expected Prescription Drug User Fee Act action date of June 17.

On the same day, Orphazyme had announced that ORARIALS-01 pivotal trial of arimoclomol in amyotrophic lateral sclerosis (ALS) did not meet both primary and secondary endpoints.

In March, arimoclomol failed to meet primary and secondary endpoints in Phase 2 and 3 trials in inclusion body myositis patients.

Read Next: Biogen CEO Says $56,000 Annual Price For Alzheimer's Drug Reflects 'Two Decades Of No Innovation'


Related Articles (ORPH)

View Comments and Join the Discussion!

Posted-In: arimoclomolBiotech News Small Cap FDA Movers Trading Ideas General Best of Benzinga

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at